Introduction

Learn more about the impact of TP53 on the outcomes of patients with myelofibrosis following hematopoietic stem cell transplant. Review the comprehensive clinical picture of the ERCC 6L2 disease, where germline variants predispose to marrow failure and myeloid malignancies. Discuss findings from a prospective trial assessing response after discontinuation of T-Po receptor agonist therapy in ITP.